0Q1G Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Eli Lilly and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$540.00 |
| 52 Week High | US$540.00 |
| 52 Week Low | US$540.00 |
| Beta | 0.32 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 3,461.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0Q1G | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | -2.6% |
| 1Y | n/a | -3.5% | 2.4% |
Return vs Industry: Insufficient data to determine how 0Q1G performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 0Q1G performed against the UK Market.
Price Volatility
| 0Q1G volatility | |
|---|---|
| 0Q1G Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0Q1G has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0Q1G's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1876 | 43,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
| 0Q1G fundamental statistics | |
|---|---|
| Market cap | CHF 610.39b |
| Earnings (TTM) | CHF 4.62b |
| Revenue (TTM) | CHF 30.07b |
132.2x
P/E Ratio20.3x
P/S RatioIs 0Q1G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0Q1G income statement (TTM) | |
|---|---|
| Revenue | US$34.12b |
| Cost of Revenue | US$7.08b |
| Gross Profit | US$27.04b |
| Other Expenses | US$21.80b |
| Earnings | US$5.24b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 5.82 |
| Gross Margin | 79.25% |
| Net Profit Margin | 15.36% |
| Debt/Equity Ratio | 233.4% |
How did 0Q1G perform over the long term?
See historical performance and comparisonDividends
0.7%
Current Dividend Yield78%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/24 21:56 |
| End of Day Share Price | 2023/11/27 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Eli Lilly and Company is covered by 63 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Alistair Campbell | Berenberg |